Literature DB >> 17210521

Is triple immunostaining with 34betaE12, p63, and racemase in prostate cancer advantageous? A tissue microarray study.

Victor WengLeong Ng1, Magdalene Koh, Soo Yong Tan, Puay Hoon Tan.   

Abstract

This study aimed to determine the usefulness of a combination of 3 immunohistochemical markers, 34/betaE12, p63 and alpha-methylacyl coenzyme A racemase (AMACR), for the diagnosis of prostate cancer using tissue microarrays (TMAs) constructed from 91 archival radical prostatectomy specimens derived from the Pathology Department files of Singapore General Hospital, Singapore. Triple immunostaining using a cocktail of these 3 antibodies was performed on TMA sections using the streptavidin-biotin method. When compared with immunohistochemical staining using the individual antibodies, we found that the triple cocktail allowed improved evaluation of basal cells in benign glands, and AMACR allowed simultaneous corroboration of malignant prostatic glands in the same section. We achieved a specificity of 100% with the triple cocktail, and sensitivity was acceptable, at 93.8%. In comparison, specificity and sensitivity of the individual antibodies were 95.5% and 97.3%, 93.3% and 93.8%, 97.0% and 95.6% for p63, 34betaE12, and AMACR, respectively. The triple cocktail offers a cost-effective way of evaluating abnormal prostatic glandular foci, in addition to maximizing the use of small tissue samples from prostatic needle biopsies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210521     DOI: 10.1309/JCFW75KGFWQUHVQD

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  8 in total

1.  Thyroid transcription factor-1 may be expressed in ductal adenocarcinoma of the prostate:a potential pitfall.

Authors:  Tony Kiat-Hon Lim; Clarence Teo; Danilo M Giron; Yew-Lam Chong; Christopher Cheng; Puay-Hoon Tan
Journal:  J Clin Pathol       Date:  2007-08       Impact factor: 3.411

2.  Evaluation of routine application of P504S, 34betaE12 and p63 immunostaining on 250 prostate needle biopsy specimens.

Authors:  Kitty Pavlakis; Konstantinos Stravodimos; Theodoros Kapetanakis; Alkiviadis Gregorakis; Sofia Athanassiadou; Olympia Tzaida; Constantinos Constantinides
Journal:  Int Urol Nephrol       Date:  2009-08-05       Impact factor: 2.370

3.  Computer-aided detection of prostate cancer on tissue sections.

Authors:  Yahui Peng; Yulei Jiang; Shang-Tian Chuang; Ximing J Yang
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-10

4.  SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer.

Authors:  Young-Kyo Seo; Nooshin Mirkheshti; Chung S Song; Soyoung Kim; Sherry Dodds; Soon C Ahn; Barbara Christy; Rosario Mendez-Meza; Michael M Ittmann; Sherry Abboud-Werner; Bandana Chatterjee
Journal:  Mol Endocrinol       Date:  2013-04-11

5.  Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma.

Authors:  Parag Deepak Dabir; Peter Ottosen; Søren Høyer; Stephen Hamilton-Dutoit
Journal:  Diagn Pathol       Date:  2012-07-16       Impact factor: 2.644

6.  A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants.

Authors:  Ning Jiang; Shimiao Zhu; Jing Chen; Yuanjie Niu; Liqun Zhou
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

Review 7.  Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.

Authors:  Tamara Sequeiros; Marta García; Melania Montes; Mireia Oliván; Marina Rigau; Eva Colás; Inés de Torres; Juan Morote; Jaume Reventós; Andreas Doll
Journal:  Biomed Res Int       Date:  2013-11-25       Impact factor: 3.411

8.  Glyoxalase 1 Expression as a Novel Diagnostic Marker of High-Grade Prostatic Intraepithelial Neoplasia in Prostate Cancer.

Authors:  Liliana Rounds; Ray B Nagle; Andrea Muranyi; Jana Jandova; Scott Gill; Elizabeth Vela; Georg T Wondrak
Journal:  Cancers (Basel)       Date:  2021-07-19       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.